2008
DOI: 10.1038/modpathol.2008.163
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue

Abstract: Fatty acid synthase (FASN) expression has been reported in many different tumors, including breast cancer. In gene microarray studies, the fatty acid synthase gene co-clustered with cytokeratins 5 and 17 and other genes that defined the basal-like subset of breast cancers. To define the use of this marker in breast pathology, a rabbit polyclonal antiserum (S143) to a peptide fragment of this gene was produced and compared with a commercially available monoclonal antibody by immunohistochemistry on various tiss… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2010
2010
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 29 publications
(38 reference statements)
0
2
0
Order By: Relevance
“…It was reported to be expressed in some benign and preinvasive female breast in basal/suprabasal cells. 34 This marker has also been significantly correlated with grade, stage, and worse OS in cancers such as ovarian cancer. 35 In triple-negative female BC, FASN was significantly associated with positive lymph nodes, but not with OS or DFS.…”
Section: Discussionmentioning
confidence: 99%
“…It was reported to be expressed in some benign and preinvasive female breast in basal/suprabasal cells. 34 This marker has also been significantly correlated with grade, stage, and worse OS in cancers such as ovarian cancer. 35 In triple-negative female BC, FASN was significantly associated with positive lymph nodes, but not with OS or DFS.…”
Section: Discussionmentioning
confidence: 99%
“…Myoepithelial/basal and some epithelial cells in human CCLs are positive for CK5/6 [19]. Though columnar cell lesions in human breast are usually negative for HER-2/neu, p53 and basal CK5/6 and CK14.…”
Section: Discussionmentioning
confidence: 99%